Goodkin D E
Multiple Sclerosis Center, Mount Zion Medical Center, University of California, San Francisco, School of Medicine 94115.
West J Med. 1994 Sep;161(3):292-8.
Corticosteroids, corticotropin, azathioprine, cyclophosphamide, and IFN-beta 1b have each had a substantial effect on the care of patients with multiple sclerosis and the design of subsequent clinical trials of experimental therapeutics for MS. The use of MRI scanning and more sensitive clinical outcome measures will possibly enable us to complete clinical trials in a fraction of the time required for earlier trials. The release of Betaseron, which favorably alters the attack rate in ambulatory patients with relapsing-remitting MS has brought a sense of renewed optimism to patients with MS, their families, and their care providers. New promising therapies for chronic progressive MS and biologic products possibly capable of enhancing the effects of IFN-beta 1b in patients with relapsing MS are setting the stage for additional important therapeutic advances in this disease.
皮质类固醇、促肾上腺皮质激素、硫唑嘌呤、环磷酰胺和干扰素β-1b均对多发性硬化症患者的治疗以及随后针对MS的实验性疗法的临床试验设计产生了重大影响。使用MRI扫描和更敏感的临床结局指标可能会使我们能够在早期试验所需时间的一小部分内完成临床试验。倍泰龙的上市有利地改变了复发缓解型MS门诊患者的发作率，给MS患者及其家人和护理人员带来了新的乐观情绪。针对慢性进展型MS的新的有前景的疗法以及可能增强复发型MS患者中干扰素β-1b疗效的生物制品，为该疾病的更多重要治疗进展奠定了基础。
